The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤ 2cm: A meta-analysis of the randomized trastuzumab trials.
Ciara Catherine Maria O'Sullivan
No relevant relationships to disclose
Ian Bradbury
No relevant relationships to disclose
Evandro De Azambuja
Honoraria - Roche/Genentech
Other Remuneration - Roche
Edith A. Perez
No relevant relationships to disclose
Priya Rastogi
No relevant relationships to disclose
Marc Spielmann
No relevant relationships to disclose
Heikki Joensuu
No relevant relationships to disclose
Karla V. Ballman
No relevant relationships to disclose
Joseph P. Costantino
Research Funding - National Cancer Institute; Roche/Genentech
Suzette Delaloge
Consultant or Advisory Role - TDM1
Honoraria - Genentech; TDM1
Research Funding - Genentech; TDM1
Dimitrios Zardavas
No relevant relationships to disclose
Martine J. Piccart-Gebhart
Consultant or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Invivis; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi ; Symphogen; Synthon; Verastem
Research Funding - Most companies
JoAnne Zujewski
No relevant relationships to disclose
Eileen McCormick Holmes
No relevant relationships to disclose
Richard D. Gelber
Research Funding - Roche/Genentech